Moxifloxacin Puren (Moxifloxacin Hydrochloride)

Moxifloxacin exerts its antibacterial effect by inhibiting two essential bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV. By binding to the quinolone‑resistance‑determining region of these enzymes, it prevents DNA supercoiling and replication, leading to rapid bacterial cell death and a broad spectrum of activity against Gram‑positive, Gram‑negative and atypical organisms.

The dosage of Moxifloxacin Puren is determined by the prescribing clinician based on the specific infection, patient characteristics and local guidelines. The prescriber selects the appropriate strength, frequency and duration of therapy, and patients should follow the exact instructions provided on the prescription label and by their healthcare professional.

The safety of moxifloxacin during pregnancy and lactation has not been definitively established, and it is generally classified as contraindicated or to be used only when the potential benefit outweighs the risk. Healthcare providers should evaluate the maternal condition, available alternatives and current regulatory guidance before prescribing to pregnant or nursing women.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation. The sales team will respond with a formal quotation and delivery options.

Compared with earlier fluoroquinolones such as ciprofloxacin or levofloxacin, moxifloxacin offers enhanced activity against Gram‑positive organisms, including Streptococcus pneumoniae, and atypical pathogens. Its pharmacokinetic profile allows once‑daily dosing for many infections, and it has a broader spectrum for respiratory infections. However, safety considerations, such as QT prolongation risk, remain similar across the class, and selection should be guided by susceptibility data and patient factors.

Moxifloxacin Puren tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources, and discard any product that shows signs of damage or discoloration.

The medication is supplied as oral tablets that are taken by mouth with or without food, according to the prescriber’s instructions. Patients should swallow the tablet whole with a glass of water and avoid crushing or chewing unless specifically directed. The dosing schedule, including the number of tablets per day and total treatment length, is individualized by the healthcare professional.

Serious adverse reactions, although uncommon, include tendon rupture (particularly of the Achilles tendon), QT interval prolongation that may precipitate cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and hepatic injury. Patients should be instructed to seek immediate medical attention if they experience sudden tendon pain, palpitations, skin blistering, severe diarrhea or jaundice.

Moxifloxacin is contraindicated in individuals with a known hypersensitivity to moxifloxacin or other fluoroquinolones. It should be avoided in patients with a history of tendon disorders related to fluoroquinolone therapy, those with significant QT prolongation, uncontrolled cardiac arrhythmias, or those taking medications that strongly prolong the QT interval. Caution is also advised for patients with severe renal or hepatic impairment, and it is generally not recommended for use in children and adolescents unless no alternative exists.